Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Birinapant + Pembrolizumab in Advanced Solid Tumors
NCT02587962Phase 2Terminated
- Sponsor
- Medivir
- Start
- Aug 2017
- Primary completion
- Feb 2020
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of birinapant in colorectal cancer (CRC), ovarian cancer, Cervical Cancer (CC), head and neck squamous cell carcinoma (HNSCC), gastroesophageal junction adenocarcinoma, sponsored by Medivir. Started Aug 2017; status: terminated.
02
Drugs
birinapant
03
Conditions
colorectal cancer (CRC)ovarian cancerCervical Cancer (CC)head and neck squamous cell carcinoma (HNSCC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT02587962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02587962.